QUALIGEN THERAPEUTICS INC (QLGN) Stock Price, Quote, News and Overview
NASDAQ:QLGN - Nasdaq - US74754R3012 - Common Stock - Currency: USD
QLGN Quote, Performance and Key Statistics
NASDAQ:QLGN (5/2/2025, 8:18:52 PM)
3.5
-0.02 (-0.57%)
The current stock price of QLGN is 3.5 USD. In the past month the price increased by 5.74%. In the past year, price decreased by -76.74%.
QLGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About QLGN
Company Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California and currently employs 4 full-time employees. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Company Info
QUALIGEN THERAPEUTICS INC
2042 Corte Del Nogal
Carlsbad CALIFORNIA 92011 US
CEO: Andrew J. Ritter
Employees: 4
Company Website: https://qlgntx.com/
Investor Relations: https://ir.qualigeninc.com/
Phone: 17609189165
QUALIGEN THERAPEUTICS INC / QLGN FAQ
What is the stock price of QUALIGEN THERAPEUTICS INC today?
The current stock price of QLGN is 3.5 USD. The price decreased by -0.57% in the last trading session.
What is the ticker symbol for QUALIGEN THERAPEUTICS INC stock?
The exchange symbol of QUALIGEN THERAPEUTICS INC is QLGN and it is listed on the Nasdaq exchange.
On which exchange is QLGN stock listed?
QLGN stock is listed on the Nasdaq exchange.
What is QUALIGEN THERAPEUTICS INC worth?
QUALIGEN THERAPEUTICS INC (QLGN) has a market capitalization of 2.59M USD. This makes QLGN a Nano Cap stock.
How many employees does QUALIGEN THERAPEUTICS INC have?
QUALIGEN THERAPEUTICS INC (QLGN) currently has 4 employees.
What are the support and resistance levels for QUALIGEN THERAPEUTICS INC (QLGN) stock?
QUALIGEN THERAPEUTICS INC (QLGN) has a support level at 3.01 and a resistance level at 3.51. Check the full technical report for a detailed analysis of QLGN support and resistance levels.
Is QUALIGEN THERAPEUTICS INC (QLGN) expected to grow?
The Revenue of QUALIGEN THERAPEUTICS INC (QLGN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the QLGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy QUALIGEN THERAPEUTICS INC (QLGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QLGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QLGN, evaluating the profitability, health, valuation and growth aspects
- QUALIGEN THERAPEUTICS INC (QLGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- QUALIGEN THERAPEUTICS INC (QLGN) Sales and EPS estimates to see what analysts future expectations are.
- QUALIGEN THERAPEUTICS INC (QLGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- QUALIGEN THERAPEUTICS INC (QLGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- QUALIGEN THERAPEUTICS INC (QLGN) Stock Chart to make your own analysis
- QUALIGEN THERAPEUTICS INC (QLGN) Latest news and press-releases to stay up to date.
Does QUALIGEN THERAPEUTICS INC (QLGN) stock pay dividends?
QLGN does not pay a dividend.
When does QUALIGEN THERAPEUTICS INC (QLGN) report earnings?
QUALIGEN THERAPEUTICS INC (QLGN) will report earnings on 2025-06-30.
What is the Price/Earnings (PE) ratio of QUALIGEN THERAPEUTICS INC (QLGN)?
QUALIGEN THERAPEUTICS INC (QLGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-56.1).
What is the Short Interest ratio of QUALIGEN THERAPEUTICS INC (QLGN) stock?
The outstanding short interest for QUALIGEN THERAPEUTICS INC (QLGN) is 7.22% of its float. Check the ownership tab for more information on the QLGN short interest.
QLGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to QLGN. When comparing the yearly performance of all stocks, QLGN is a bad performer in the overall market: 87.61% of all stocks are doing better.
QLGN Financial Highlights
Over the last trailing twelve months QLGN reported a non-GAAP Earnings per Share(EPS) of -56.1. The EPS decreased by -1416.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -343.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QLGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to QLGN. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 62.96% and a revenue growth -100% for QLGN